RCUS
Arcus Biosciences, Inc.·Healthcare
22.39
0.224%(+0.05)
Close PriceLast Updated: — ET
52W L: $7.0652W H: $26.40
RCUS NEWS
defenseworld.net
3d ago
Financial Analysis: Arcus Biosciences (NYSE:RCUS) vs. Immunovant (NASDAQ:IMVT)
Arcus Biosciences (NYSE: RCUS - Get Free Report) and Immunovant (NASDAQ: IMVT - Get Free Report) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, profitability and earnings. Institutional and Insider Ownership 92.9% of Arcus Biosciences
businesswire.com
4d ago
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 7,850 shares of the Company's common stock at an exercise price per share of $22.65, which was the.
defenseworld.net
Apr 3
Arcus Biosciences (NYSE:RCUS) Trading Up 5.4% Following Analyst Upgrade
Arcus Biosciences, Inc. (NYSE: RCUS - Get Free Report) shares were up 5.4% on Thursday after Wedbush raised their price target on the stock from $37.00 to $41.00. Wedbush currently has an outperform rating on the stock. Arcus Biosciences traded as high as $22.59 and last traded at $23.0270. Approximately 293,340 shares were traded during mid-day
247wallst.com
Apr 1
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms.
businesswire.com
Mar 24
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune disorders, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 7,050 shares of the Company's common stock at an exercise price per share of $21.41, which was th.
businesswire.com
Mar 9
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 17,050 shares of the Company's common stock at an exercise price per share of $23.43, which was th.
